Interactions of oritavancin, a new semi-synthetic lipoglycopeptide, with lipids extracted from Staphylococcus aureus.
Oritavancin, a lipoglycopeptide with marked bactericidal activity against vancomycin-resistant Staphylococcus aureus and enterococci, induces calcein release from CL:POPE and POPG:POPE liposomes, an effect enhanced by an increase in POPG:POPE ratio, and decreased when replacing POPG by DPPG (Domenech et al., Biochim Biophys Acta 2009; 1788:1832-40). Using vesicles prepared from lipids extracted from S. aureus, we showed that oritavancin induces holes, erosion of the edges, and decrease of the thickness of the supported lipid bilayers (atomic force microscopy; AFM). Oritavancin also induced an increase of membrane permeability (calcein release) on a time- and dose-dependent manner. These effects were probably related to the ability of the drug to bind to lipid bilayers as shown by 8-anilino-1- naphthalene sulfonic acid (ANS) assay. Interaction of oritavancin with phospholipids at the level of their glycerol backbone and hydrophobic domain was studied by monitoring changes of Laurdan excitation generalized polarization (GP(ex)) and 1,6-diphenyl-1,3,5-hexatriene (DPH) fluorescence anisotropy upon temperature increase. Oritavancin increased GP(ex) values and the transition temperature, indicating a more ordered structure at the level of the glycerol backbone. Oritavancin slightly decreased DPH fluorescence depolarization intensities, suggesting an increase in fluidity at the level of acyl chains. Together, our data confirm the interaction of oritavancin with lipids and the potential role of a rigidifying effect at the level of glycerol backbone for membrane permeabilization. This work shows how AFM and biophysical methods may help in characterizing drug-membrane interactions, and sheds further light on the mode of action of oritavancin.
Domenech
Oscar
O
Université catholique de Louvain, Louvain Drug Research Institute, Unité de pharmacologie cellulaire et moléculaire, UCL 73.70, avenue E. Mounier 73, B-1200 Bruxelles, Belgium.
Dufrêne
Yves F
YF
Van Bambeke
Françoise
F
Tukens
Paul M
PM
Mingeot-Leclercq
Marie-Paule
MP
D000817:Anilino Naphthalenesulfonates / Q000737:chemistry; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D004161:Diphenylhexatriene / Q000737:chemistry; D005454:Fluorescence Polarization; D006020:Glycopeptides / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D008051:Lipid Bilayers / Q000737:chemistry / Q000378:metabolism; D008055:Lipids / Q000737:chemistry* / Q000302:isolation & purification; D000077427:Lipoglycopeptides; D018625:Microscopy, Atomic Force / Q000379:methods; D010539:Permeability / Q000187:drug effects; D010714:Phosphatidylethanolamines / Q000737:chemistry; D010715:Phosphatidylglycerols / Q000737:chemistry; D011485:Protein Binding; D013211:Staphylococcus aureus / Q000737:chemistry*; D013997:Time Factors; D053835:Unilamellar Liposomes / Q000737:chemistry* / Q000378:metabolism; D014640:Vancomycin / Q000031:analogs & derivatives
D000817:Anilino Naphthalenesulfonates; D000900:Anti-Bacterial Agents; D004161:Diphenylhexatriene; D006020:Glycopeptides; D008051:Lipid Bilayers; D008055:Lipids; D000077427:Lipoglycopeptides; D010714:Phosphatidylethanolamines; D010715:Phosphatidylglycerols; D053835:Unilamellar Liposomes; C515594:8-anilino-1-naphthalenesulfonic acid; C057561:1-palmitoyl-2-oleoylphosphatidylethanolamine; C060037:1-palmitoyl-2-oleoylglycero-3-phosphoglycerol; C100708:oritavancin; D014640:Vancomycin; C030345:1,2-dipalmitoylphosphatidylglycerol